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Background: MicroRNAs (miRNAs) are a family of endogenous, small and non-coding RNAs that regulate gene
expression negatively at the post-transcriptional level by suppressing translation or degrading target mRNAs, and
are involved in diverse biological and pathological processes. Single nucleotide polymorphisms (SNPs) which are
located in the miRNA-coding genes may participate in the process of development and diseases by altering the
expression of mature miRNA. Recent studies investigating the association between hsa-mir-499 polymorphism
(rs3746444) and cancer risk have yielded conflicting results.
Methods: In this meta-analysis, we conducted a search of case–control studies on the associations of SNP
rs3746444 with susceptibility to cancer in electronic databases. A total of 31 studies involving 12799 cases and
14507 controls were retrieved and the strength of the association was estimated by pooled odds ratios (ORs) and
95% confidence intervals (CIs). Hardy-Weinberg equilibrium (HWE) was assessed by the goodness-of-fit chi-square
test in controls. Subgroup analyses were done by racial descent and cancer type. Publication bias of literatures was
evaluated by visual inspection of funnel plots and the linear regression asymmetry test by Egger et al. Sensitivity
analysis was conducted by excluding one study at a time to examine the influence of individual data set on the
pooled ORs.
Results: Overall, significant association between rs3746444 polymorphism and susceptibility to cancer was
identified in TC versus TT and TC/CC versus TT (dominant) models. In the stratified analyses, increased risks were
found in Asians, but not in Caucasians in all comparison models tested. Moreover, significant association with an
increased risk was found in Chinese population. Also, much higher significant association with increased cancer
risks were found in Iranian population. In different cancer types, a decreased risk was found in esophageal cancer.
Conclusion: Our meta-analysis suggested that hsa-mir-499 rs3746444 T > C polymorphism is associated with the
risk of cancer in Asians, mainly in Iranian and Chinese population. However, rs3746444 T > C polymorphism is
negatively associated with the risk of esophageal cancer.
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In early 1990s, microRNAs (miRNAs) were first discov-
ered through analysis of developmental timing mutants in
C. elegans by several groups, simultaneously [1,2]. In the
last decade, the study of miRNA biology has attracted
remarkable attention, resulting in rapid advances, and
revealing miRNAs as key gene regulators in diverse bio-
logical pathways [3]. miRNAs participate in regulation of
stem cell functions [4], development [5], drug resistance
[6], metabolism and metabolic disorders [7], cardiovascu-
lar [8] and malignant diseases [9,10].
miRNAs are hairpin-derived RNAs ~20-24 nucleotides
long, which post-transcriptionally repress the expression
of target genes usually by binding to the 3′-untranslated
region (3′ UTR) of messenger RNA (mRNA) in a broad
range of organisms in both normal physiological and
disease contexts [11,12]. The majority of human miRNA
loci are located within intronic regions and are transcribed
by RNA polymerase II as part of their hosting tran-
scription units [13]. Typically, following RNA polymer-
ase II-mediated transcription, the long primary precursors
(pri-miRNAs) are cleaved by the nuclear RNase III
(Drosha) to release ~70 nt pre-miRNAs [14]. The result-
ing transcripts adopt a stem-loop structure and are then
exported to the cytoplasm where they are subsequently
processed by another RNase III (Dicer) to generate mature
double-stranded ~22 nt miRNAs [15]. Subsequently, one
strand of this duplex is incorporated into an Argonaute-
containing RNA-induced silencing complex (RISC), result-
ing in the translational repression and/or degradation of
their target mRNAs [16].
Recent evidences support that single nucleotide poly-
morphisms (SNPs), occurring in DNA sequences of
miRNA-coding genes or in miRNA-binding site in mRNAs,
contribute to the biogenesis and functions of miRNAs [17].
Gain/loss-of-function of miRNA polymorphisms may result
in enhancing of the combination of the miRNA to the
targets or losing control of the mRNAs, which may be
associated with diseases [18].
Reports on the associations between SNPs in pre-miRNA
or SNPs in binding sites in 3′ UTR of miRNA targeting
mRNAs and human diseases have provided new insights
into the molecular mechanisms of pathophysiological pro-
cesses in humans. rs4846049 (G > T) of MTHFR gene is
associated with increased risk for coronary heart diseases,
and the potentially pathogenetic mechanism may be
SNP-modified posttranscriptional gene regulation by
miRNA-149 to MTHFR [19]. MiR-196a binding-site SNP
regulates RAP1A expression contributing to esophageal
squamous cell carcinoma risk and metastasis [20]. A
miRNA-binding SNP (1010A/G) located within 3′-UTR
of HOXB5 is associated with gene expression and may be
a promising prognostic factor for bladder cancer [21]. The
A to G base change of rs999885 may provide a protectiveeffect against chronic HBV infection but an increased risk
for HCC in HBV persistent carriers by altering the expres-
sion of the miR-106b-25 cluster [22]. miR-200b/200c/429-
binding site polymorphism in the 3′-UTR of AP-2α gene
is associated with cisplatin resistance, suggesting that SNP
(rs1045385) A > C variation may be a potential prognostic
marker for cisplatin treatment [23].
To date, many studies explored the association between
rs3746444 T > C SNP in hsa-mir-499 and susceptibility to
diseases, such as breast cancer [24-26], lung cancer [27],
congenital heart disease [28], dilated cardiomyopathy [29],
gallbladder cancer [30], squamous cell carcinoma of the
head and neck [31], chronic obstructive pulmonary dis-
ease [32], liver cancer [33], rheumatoid arthritis [34],
coronary artery disease [35], and colorectal cancer [36].
Especially, one study suggested that miR-499 rs3746444*T
alleles might be protective for breast cancer [37], but
another found that the miR-499 rs3746444 C allele
increased cancer risk in the allelic contrast model and
in the dominant model, especially in breast cancer
[38], while another study showed that no significant
associations were observed between rs3746444 in miR-
499 and breast cancer susceptibility [39]. Recently, a
meta-analysis suggested that polymorphism of hsa-
mir-499 rs3746444 T > C was not associated with in-
creased susceptibility to cancers [40,41], while other
systematic analysis supported that hsa-mir-499 rs3746444
polymorphism contributed to the susceptibility to cancers
[42-45].
The results of these observations remain controversial
and inconclusive. In the present study, we conducted a
meta-analysis in order to derive more precise and more
comprehensive estimation of the associations between
the SNP hsa-mir-499 rs3746444 T > C and susceptibility




We performed a publication search in PubMed, EMBASE,
ISI Web of Science, The Cochrane Library, ScienceDirect,
EBSCO, Ovid, Wiley Online Library, and HighWire
databases with the following search terms: (miR-499
OR rs3746444) AND (cancer), by two independent in-
vestigators (Chen Chen and Shenglan Yang, last search
update: June 29, 2014). Hand searches were also per-
formed to identify additional articles in the reference
lists of included articles not retrieved by initial electronic
search. Publication date and publication language were
not restricted in our search. All studies matching the
inclusion criteria were retrieved for further examination
and data extraction. All of the investigators have received
training in literature search, statistics and evidence-based
medicine.
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Studies included in current meta-analysis had to meet
all the following criteria: (1) evaluated the associations
between the hsa-mir-499 rs3746444 polymorphism and
cancer risk; (2) studied on human beings; (3) diseases
were confirmed by histology, imaging or pathology; (4) a
case–control design; (5) detailed genotype data were
provided for the calculation of odds ratio (OR) and 95%
confidence interval (CIs); (6) if serial studies of the same
population from the same group were reported, the
latest study was included. Studies were excluded when
they represented duplicates of previous publications, or
were meta -analyses, meeting abstracts, letters, reviews,
or editorial articles.
Data extraction
Two investigators (Chen Chen and Shenglan Yang) inde-
pendently extracted data from the included studies using
a standard protocol and data-collection form according
to the inclusion criteria listed above, and reached con-
sensus on all items. Data extracted from eligible studies
included the first author’s name, year of publication,
country of origin, ethnicity, cancer type, genotyping
method, total numbers of cases and controls, and geno-
type frequencies of cases and controls. For study includ-
ing subjects of different countries of origin group from
same ethnicity, we combined them together. The ethnic
descents were categorized as Caucasian or Asian. If dif-
ferent results were generated, the two authors would
check the data and have had a discussion to come to an
agreement. Two senior investigators (Yan Wang and Dao
Wen Wang) were invited to the discussion if disagreement
still existed.
Statistical analysis
For each study, the departure of frequencies of hsa-mir-499
polymorphism from expectation under Hardy-Weinberg
equilibrium (HWE) was assessed by the goodness-of-fit
chi-square test in controls. P < 0.05 was considered repre-
sentative of a departure from HWE.
OR corresponding to 95% CI was used to assess the
strength of association between hsa-miR-499 rs3746444
T > C polymorphism and susceptibility to cancer risk.
The significance of the pooled OR was determined by
the Z-test, and P < 0.05 was considered as statistically
significant. Pooled ORs were calculated for allele frequency
comparison (C versus T, TC versus TT, CC versus TT,
TC/CC versus TT (dominant) and CC versus TC/TT
(recessive)), respectively. Subgroup analyses were done
by racial descent and cancer type. Statistical heterogeneity
among the studies was estimated using chi-square-based
Q-test, a P value greater than 0.1 indicates no significant
heterogeneity and the pooled OR was estimated by
the fixed-effects model (the Mantel-Haenszel method);otherwise, the random-effects model (the DerSimonian
and Laird method) was employed [46]. Publication bias of
literatures was evaluated by funnel plots and the linear
regression asymmetry test by Egger et al. [47]. An asym-
metric plot suggests a possible publication bias and the
P value of Egger’s test less than 0.05 was considered rep-
resentative of statistically significant publication bias.
Sensitivity analysis was conducted by deleting one study
at a time to examine the influence of individual data set
on the pooled ORs.
All of the statistical tests were performed with Review
Manage (v.4.2; Oxford, England) and STATA software
version 11.0 (STATA Corporation, College Station, TX,
USA). All the P values are two-sided.
Results
Study characteristics
After first search in PubMed, EMBASE, ISI Web of
Science, The Cochrane Library, ScienceDirect, EBSCO,
Ovid, Wiley Online Library, and HighWire databases,
70, 76, 116, 0, 2080, 86, 23, 104, and 202 articles, re-
spectively, were retrieved. Of these, 55 articles were
relevant to the search words (Figure 1). After further
manual search of reference lists, one more study was
included. Then, 25 studies were excluded (7 meeting
abstracts, 13 meta-analyses, 1 without detailed allele
frequency data, and 4 non-case–control studies) and
finally 31 studies involving a total of 12799 disease
cases and 14507 controls met the inclusion criteria and
were subjected to further examination. Characteristics
of included studies are summarized in Table 1, includ-
ing ethnicity, genotype detection method and cancer
type. All studies were case–control studies, including 8
liver cancer studies [33,48-54], 4 breast cancer studies
[24-26,55], 4 gastric cancer studies [56-59], 3 colorec-
tal cancer studies [36,60,61], 2 lung cancer studies
[27,62], 2 esophageal cancer studies [63,64], and others
(1 cervical cancer study [65], 1 bladder cancer study
[66], 1 prostate cancer study [67], 1 head and neck
cancer study [31], 1 gallbladder cancer study [30], 1
childhood acute lymphoblastic leukemia [68], 1 renal
cell carcinoma [69] and 1 oral squamous cell carcin-
oma [70]). Cancers were histologically or pathologic-
ally diagnosed in all studies. There were 28 studies of
Asian descents (16 Chinese, 4 Indian, 3 Korean, 2
Iranians and 3 others) and 3 studies of Caucasian
descents. Several genotyping methods were employed
in the studies including Taqman, polymerase chain
reaction-restriction fragment length polymorphism
(PCR-RFLP), DNA sequencing, high resolution melting
analysis (HRMA), T-ARMS-PCR, MALDI-TOF MS and
Sequenom MassARRAY. PRISMA checklist was gener-
ated to provide detailed description of this meta-analysis
(Additional file 1: Table S1).
Records retrieved from PubMed (70), EMBASE (76), ISI Web of Science (116), The 
Cochrane Library (0), ScienceDirect (2080), EBSCO (86), Ovid (23), Wiley Online Library 
(104), and HighWire (202) databases.
Last update: June, 29, 2013
Full text of the remain 55 records were obtained
Excluded for improper titles 
and/or abstracts
31 studied selected
25 record excluded :
7: meeting abstract
13: meta-analysis
1: Lack of SNP phenotype
4: not case-control study
1 record included :
Manual research of reference lists
Figure 1 Flow diagram of study identification.
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The association between hsa-mir-499 rs3746444 poly-
morphism and susceptibility to cancer was analyzed in
31 independent studies. The results are shown in Table 2
and Additional file 2: Figures S1, S2 and S3. Significant
association between rs3746444 polymorphism and sus-
ceptibility to cancer was identified in TC versus TT and
TC/CC versus TT (dominant) models, when all the eli-
gible studies were pooled (C versus T: OR = 1.08, 95%
CI 0.99-1.17, P = 0.08; TC versus TT: OR = 1.11, 95%
CI 1.00-1.23, P = 0.04; CC versus TT: OR = 1.02, 95%
CI 0.85-1.22, P = 0.85; TC/CC versus TT (dominant):
OR = 1.11, 95% CI 1.01-1.23, P = 0.03; CC versus TC/TT
(recessive): OR = 0.98, 95% CI 0.81-1.17, P = 0.79). Next,
subgroup analyses were performed. Twenty-eight out of
the thirty-one included studies were conducted in Asian
population. In ethnicity subgroup analysis, significantly
increased risks were found in Asians (TC versus TT:
OR = 1.14; 95% CI = 1.02-1.27, P = 0.02; TC/CC versus
TT (dominant): OR = 1.14; 95% CI = 1.02-1.27, P = 0.02),
consistently. This increased risk of cancer was especially
significant in Iranian (C versus T: OR = 1.57; 95%
CI = 1.23-2.01, P = 0.0003; CC versus TT: OR = 2.23;
95% CI = 1.42-3.51, P = 0.0005; CC versus TC/TT (reces-
sive): OR = 2.23; 95% CI = 1.44-3.45, P = 0.0003) and
Chinese population (TC versus TT: OR = 1.18; 95% CI =
1.02-1.35, P = 0.02). However, no significant association
between hsa-mir-499 rs3746444 T > C polymorphism andcancer risk was found in Caucasians in any of the genetic
models tested. Further subgroup analysis based on can-
cer type revealed a decreased risk for esophageal cancer
(C versus T: OR = 0.80; 95% CI = 0.66-0.98, P = 0.03).
Publication bias
Begg’s funnel plot and Egger’s test were performed to as-
sess the publication bias of included studies. Symmetrical
funnel plots were obtained in all comparison models
(Figure 2). Further, Egger’s test confirmed the absence
of publication bias in all genetic models (P > 0.05).
Sensitivity analysis
Exclusion of one study at a time was performed to
examine the influence of the individual data set to the
pooled ORs. Analyses were performed using STATA by
means of the metainf program. Results showed that the
pooled OR estimates were similar with those of the
excluded studies (Figure 3).
Discussion
In the present study, hsa-mir-499 rs3746444 polymorph-
ism and susceptibility to cancer was evaluated in different
genetic models in 12799 cancer cases and 14507 controls.
Significant association between rs3746444 polymorphism
and susceptibility to cancer was identified in TC versus
TT and TC/CC versus TT (dominant) models. Subgroup
analysis absed on ethnicity revealed significantly increased
able 1 Characteristics of studies included in the meta-analysis









of controls (n, (%))
Allele frequencies
of controls (n, (%))
TT TC CC T C TT TC CC T C
Hu 2009 China Asian Breast cancer 0.057 1009/1093 707 (70) 258 (25.6) 44 (4.4) 1672 (82.9) 346 (17.1) 816 (74.7) 248 (22.7) 29 (2.6) 1880 (86) 306 (14)
Tian 2009 China Asian Lung cancer 0.404 1058/1035 781 (73.8) 253 (23.9) 24 (2.3) 1815 (85.8) 301 (14.2) 755 (73.0) 254 (24.5) 26 (2.5) 1764 (85.2) 306 (14.8)
Catucci 2010 Italy; Germany Caucasian Breast cancer 0.284 1579/2167 950 (60.16) 545 (34.52) 84 (5.32) 2445 (77.4) 713 (22.6) 1305 (60.22) 742 (34.24) 120 (5.54) 3352 (77.3) 982 (22.7)
Liu 2010 US Caucasian Squamous cell
carcinoma of the
head and neck
0.441 1109/1130 745 (67.2) 309 (27.9) 55 (4.9) 1799 (81.1) 419 (18.9) 710 (62.8) 366 (32.4) 54 (4.8) 1786 (79) 474 (21)
Srivastava 2010 India Asian Gallbladder cancer 0.566 230/230 112 (48.7) 97 (42.2) 21 (9.1) 321 (69.8) 139 (30.2) 121 (52.6) 94 (40.9) 15 (6.5) 336 (73) 124 (27)
Okubo 2010 Japan Asian Gastric cancer 0.048 697/552 364 (65.9) 151 (27.4) 37 (6.7) 879 (79.6) 225 (20.4) 466 (66.9) 198 (28.4) 33 (4.7) 1130 (81.1) 264 (18.9)
Akkiz 2011 Turkish Asian Hepatocellular
carcinoma
0.036 222/222 45 (20.3) 87 (39.2) 90 (40.5) 177 (40) 267 (60) 47 (21.2) 93 (41.9) 82 (36.9) 187 (42.1) 257 (57.9)
George 2011 India Asian Prostate cancer 0.073 159/230 48 (30.2) 98 (61.6) 13 (8.2) 194 (61) 124 (39) 104 (45.2) 92 (40.0) 34 (14.8) 300 (65.2) 160 (34.8)
Min 2011 Korea Asian Colorectal cancer 0.453 446/502 292 (65.5) 142 (31.8) 12 (2.7) 726 (81.4) 166 (18.6) 334 (66.5) 154 (30.7) 14 (2.8) 822 (81.9) 182 (18.1)
0 Mittal 2011 India Asian Bladder cancer 0.029 212/250 95 (44.8) 92 (43.4) 25 (11.8) 282 (66.5) 142 (33.5) 121 (48.4) 94 (37.6) 35 (14.0) 336 (67.2) 164 (32.8)
1 Vinci 2011 Italy Caucasian Lung cancer 0.503 101/129 53 (52.5) 41 (40.6) 7 (6.9) 147 (72.8) 55 (27.2) 70 (54.2) 48 (37.2) 11 (8.6) 188 (72.9) 70 (27.1)
2 Zhou 2011 China Asian Cervical squamous
cell carcinoma
0.005 226/309 134 (59.3) 84 (37.2) 8 (3.5) 352 (77.9) 100 (22.1) 223 (68.2) 71 (23.0) 15 (4.8) 517 (83.7) 101 (16.3)
3 Alshatwi 2012 Saudi Asian Breast cancer 0.304 92/89 27 (29.3) 57 (62) 8 (8.7) 111 (60.3) 73 (39.7) 40 (45) 36 (40.4) 13 (14.6) 116 (65.2) 62 (34.8)
4 Kim 2012 Korea Asian Hepatocellular
carcinoma
0.278 159/201 109 (68.6) 47 (29.5) 3 (1.9) 265 (83.3) 53 (16.7) 120 (59.7) 74 (36.8) 7 (35) 314 (78.1) 88 (21.9)
5 Umar 2012 India Asian Esophageal cancer 0.087 289/309 155 (53.6) 122 (42.2) 12 (4.2) 432 (74.7) 146 (25.3) 149 (48.2) 140 (45.3) 20 (6.5) 438 (70.9) 180 (29.1)
6 Xiang 2012 China Asian Hepatocellular
carcinoma
0.284 100/100 36 (36) 40 (40) 24 (24) 112 (56) 88 (44) 54 (54) 36 (36) 10 (10) 144 (72) 56 (28)
7 Zhou 2012 China Asian Hepatocellular
carcinoma
0.1 186/483 141 (75.8) 41 (22.0) 4 (2.2) 323 (86.8) 49 (13.2) 371 (76.8) 100 (20.7) 12 (2.48) 842 (87.2) 124 (12.8)
8 Ahn 2012 Korea Asian Gastric cancer 0.829 461/477 323 (70.1) 123 (26.7) 15 (3.3) 769 (83.4) 153 (16.6) 299 (66.9) 134 (30.0) 14 (3.1) 732 (81.9) 162 (18.1)
9 Hasani 2013 Iran Asian Childhood acute
lymphoblastic
leukemia
0.249 75/115 35 (46.7) 28 (37.3) 12 (16.0) 98 (65.3) 52 (34.7) 61 (53.0) 42 (36.5) 12 (10.4) 164 (71.3) 66 (28.7)
0 Wei 2013 China Asian Esophageal cancer 0.036 380/380 291 (81.3) 60 (16.8) 7 (2.0) 642 (89.7) 74 (10.3) 289 (76.9) 76 (20.2) 11 (2.9) 654 (87) 98 (13)
1 Zou 2013 China Asian Hepatocellular
carcinoma
0.005 185/185 136 (73.5) 44 (23.8) 5 (2.7) 316 (85.4) 54 (14.6) 123 (66.5) 48 (25.9) 14 (7.6) 294 (79.5) 76 (20.5)
2 Lv 2013 China Asian Colorectal cancer 0.082 346/504 258 (74.6) 86 (24.6) 2 (5.8) 602 (87) 90 (13) 366 (72.6) 121 (24.0) 17 (3.4) 853 (84.6) 155 (15.4)
3 Hu 2013 China Asian Colorectal cancer 0.162 276/373 157 (74.4) 49 (23.2) 5 (2.4) 363 (86) 59 (14) 282 (75.6) 81 (21.7) 10 (2.7) 645 (86.5) 101 (13.5)
4 Shan 2013 China Asian Hepatocellular
carcinoma
0.005 172/185 128 (74.4) 37 (21.5) 7 (4.1) 293 (85.2) 51 (14.8) 123 (66.7) 48 (25.8) 14 (7.5) 294 (79.5) 76 (20.5)
5 Wu 2013 China Asian Gastric cancer 0.854 200/211 149 (74.5) 47 (23.5) 4 (2.0) 345 (86.3) 55 (13.7) 166 (78.7) 42 (19.9) 3 (1.4) 374 (88.6) 48 (11.4)














































able 1 Characteristics of studies included in the meta-analysis (Continued)
7 Du 2014 China Asian Renal cell cancer 0.594 354/362 251 (70.9) 94 (26.6) 9 (2.5) 596 (84.2) 112 (15.8) 255 (70.4) 96 (26.5) 11 (3.1) 606 (83.7) 118 (16.3)
8 Huo 2014 China Asian Oral squamous
cell carcinoma
0.419 872/667 616 (70.6) 243 (27.9) 13 (1.5) 1475 (84.6) 269 (15.4) 505 (75.7) 148 (22.2) 14 (2.1) 1158 (86.8) 176 (13.2)
9 Ma 2014 China Asian Hepatocellular
carcinoma
<0.001 984/969 724 (73.6) 241 (24.5) 19 (1.9) 1689 (85.8) 279 (14.2) 765 (79.0) 179 (18.4) 25 (2.6) 1709 (88.2) 229 (11.8)
0 Pu 2014 China Asian Gastric cancer 0.082 196/504 141 (71.9) 50 (25.5) 5 (2.6) 332 (84.7) 60 (15.3) 366 (72.6) 121 (24.0) 17 (3.4) 853 (84.6) 155 (15.4)
1 Chu 2014 China Asian Hepatocellular
carcinoma

























Table 2 Meta-analysis for the hsa-miR-499 rs3746444 T > C polymorphism and cancer risk
Genetic model Na C vs T TC vs TT CC vs TT TC/CC vs TT (dominant) CC vs TC/TT (recessive)
Pooled OR
[95% CI]
P hb P c Pooled OR
[95% CI]
P hb P c Pooled OR
[95% CI]
P hb P c Pooled OR
[95% CI]
P hb P c Pooled OR
[95% CI]
P hb P c
Total 31 1.08 (0.99-1.17) <0.00001 0.08 1.11 (1.00-1.23) <0.00001 0.04 1.02 (0.85-1.22) 0.002 0.85 1.11 (1.01-1.23) <0.00001 0.03 0.98 (0.81-1.17) 0.001 0.79
Ethnicities
Asian 28 1.10 (1.00-1.21) <0.00001 0.06 1.14 (1.02-1.27) <0.00001 0.02 1.02 (0.82-1.27) 0.0009 0.86 1.14 (1.02-1.27) <0.00001 0.02 0.97 (0.78-1.20) 0.0004 0.76
Chinese 16 1.11 (0.95-1.28) <0.00001 0.18 1.18 (1.02-1.35) 0.0002 0.02 0.92 (0.65-1.32) 0.001 0.66 1.15 (0.99–1.34) <0.00001 0.07 0.89 (0.63-1.24) 0.004 0.48
Indian 4 1.03 (0.87-1.23) 0.19 0.70 1.26 (0.84-1.88) 0.005 0.26 0.91 (0.63-1.31) 0.33 0.62 1.18 (0.84-1.65) 0.02 0.34 0.79 (0.52-1.20) 0.18 0.27
Korean 3 0.94 (0.78-1.13) 0.26 0.49 0.89 (0.72-1.11) 0.27 0.31 0.89 (0.54-1.48) 0.62 0.66 0.93 (0.75-1.15) 0.25 0.48 0.95 (0.58-1.57) 0.65 0.84
Iranians 2 1.57 (1.23-2.01) 0.34 0.0003 0.99 (0.68-1.45) 0.54 0.97 2.23 (1.42-3.51) 0.54 0.0005 1.38 (1.00-1.91) 0.78 0.05 2.23 (1.44-3.45) 0.41 0.0003
Others 3 1.11 (0.96-1.29) 0.88 0.16 1.22 (0.77-1.95) 0.04 0.40 1.24 (0.89-1.73) 0.67 0.20 1.19 (0.86-1.63) 0.16 0.30 1.13 (0.77-1.67) 0.21 0.53
Caucasian 3 0.95 (0.88-1.04) 0.39 0.28 0.93 (0.77-1.12) 0.12 0.44 0.96 (0.76-1.20) 0.97 0.71 0.93 (0.80-1.09) 0.19 0.36 0.98 (0.78-1.22) 0.87 0.83
Cancer type
Liver cancer 8 1.12 (0.85-1.54) <0.00001 0.46 1.14 (0.85-1.54) 0.0002 0.38 1.03 (0.55-1.92) 0.0005 0.93 1.15 (0.82-1.61) <0.00001 0.43 0.99 (0.57-1.71) 0.002 0.97
Breast cancer 4 1.25 (0.99-1.57) 0.0002 0.06 1.15 (0.91-1.45) 0.04 0.24 1.43 (0.87-2.34) 0.009 0.16 1.24 (0.99-1.55) 0.03 0.06 1.30 (0.75-2.24) 0.002 0.35
Gastric cancer 4 1.03 (0.90-1.18) 0.49 0.66 0.98 (0.83-1.15) 0.54 0.79 1.21 (0.84-1.75) 0.66 0.31 1.01 (0.86-1.17) 0.53 0.95 1.22 (0.85-1.76) 0.66 0.28
Colorectal cancer 3 0.96 (0.82-1.13) 0.42 0.62 1.05 (0.87-1.26) 0.96 0.64 0.61 (0.23-1.62) 0.09 0.32 1.00 (0.84-1.20) 0.73 0.99 0.61 (0.23-1.58) 0.10 0.31
Lung cancer 2 0.96 (0.82-1.13) 0.83 0.64 0.98 (0.81-1.18) 0.60 0.84 0.88 (0.54-1.44) 0.92 0.61 0.97 (0.81-1.16) 0.68 0.74 0.87 (0.54-1.42) 0.84 0.59
Esophageal cancer 2 0.80 (0.66-0.98) 0.75 0.03 0.81 (0.63-1.04) 0.80 0.10 0.60 (0.33-1.08) 0.88 0.09 0.79 (0.62-1.00) 0.83 0.05 0.64 (0.36-1.14) 0.93 0.13
Others 8 1.11 (0.97-1.26) 0.05 0.13 1.27 (0.98-1.65) <0.0001 0.07 0.99 (0.79-1.25) 0.80 0.93 1.12 (0.98-1.53) 0.0004 0.07 0.91 (0.72-1.16) 0.37 0.46
aNumber of comparisons.
bP h value of Q-test for heterogeneity test. Random-effects model was used when P value for heterogeneity test <0.1; otherwise, fix-effects model was used.




















Figure 2 Begg’s funnel plot for publication bias test. (A) C versus T; (B) TC versus TT; (C) CC versus TT; (D) TC/CC versus TT (dominant) and
(E) CC versus TC/TT (recessive). Each point represents a separate study for the indicated association. Log OR, natural logarithm of OR.
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http://www.biomedcentral.com/1471-2350/15/126risk in Asians (TC versus TT and TC/CC versus TT
(dominant), but there was no significant association in
Caucasians in all genetic models. This association was
especially marked in Iranians (C versus T; CC versus
TT and CC versus TC/TT (recessive) and a significant
association was also identified in Chinese (TC versus
TT) However, subgroup analysis based on cancer type re-
vealed a decreased risk for esophageal cancer (C versus T).
Many studies investigated the role of SNPs presented
in precursor and mature miRNAs, and their influences
on susceptibility and progression of various diseases.
miRNA-associated SNPs can have direct or indirect ef-
fects: 1) direct effects are produced by the SNPs in the
pri-miRNA, pre-miRNA or mature miRNA that impair or
enhance miRNA processing or function; 2) indirect effectsFigure 3 Sensitivity analysis of the influence of a single study on th
(C) CC versus TT; (D) TC/CC versus TT (dominant) and (E) CC versus TC/TT
Circles and dashed lines correspond to the specific OR and 95% CI withoare derived from the SNPs in miRNA promoters that
affect transcription and SNPs in an mRNA that create or
destroy a target site [71].
Genome-wide patterns of human polymorphisms in
miRNAs and miRNA target sites in 3′ UTRs of mRNAs
revealed that only ~10% of human pre-miRNAs have
documented SNPs, and <1% of mature miRNAs have
SNPs in the functional seed region [72]. hsa-mir-499
rs3746444 polymorphism is located in the seed region
of the mature miR-499 sequence. This T > C poly-
morphism-resulted mismatch may affect target mRNA
expression. Several case–control studies have investi-
gated the association between rs3746444 polymorphism
and risks of various cancers. However, the results were
controversial.e overall meta-analysis estimate. (A) C versus T; (B) TC versus TT;
(recessive). The solid lines correspond to the pooled OR and 95% CI.
ut omitted study.
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http://www.biomedcentral.com/1471-2350/15/126Different from past studies, we analyzed the specific
association among different ethnic groups throughout
Asia. In this meta-analysis, we first found that rs3746444
polymorphism was associated with increased cancer risk
mainly in Asian population, especially in Chinese and
Iranians. It is important to notice that, although
rs3746444 polymorphism contributes to cancer risk in
Chinese and Iranians, the genetic models are different.
The genetic variations between Chinese Han population
and Arabian population may contribute to the differences.
Interestingly, we also found that rs3746444 polymorphism
showed a decreased risk in esophageal cancer. This sug-
gests that potentially different mechanisms may underlie
tumorgenesis in different pathological backgrounds and
the environment variations.
It has been suggested that miRNAs may influence
gene expression of ~30% of protein-coding genes by
binding to the mRNA incompletely, and a miRNA may
affect multiple target mRNAs involved in same patho-
physiological progress [3,73]. This means that rs3746444
polymorphism may contribute to single gene function in
certain disease model at molecular level. When taken to-
gether in epidemiological studies of populations, various
effects of rs3746444 polymorphism on different genes
may result in different associations with diseases at
phenotype level.
Our meta-analysis pooled the largest numbers of cases
and controls from included studies, which significantly
increases the statistical power but some limitations
should be considered. Firstly, lack of the consideration
of combined genetic factors together with environmental
exposures, while a more precise analysis needs to be
conducted if more detailed data are available. Secondly,
although sensitivity analysis showed that each study can
not affect the overall results, some heterogeneity was
evident in some of the comparisons. This may be due to
different ethnicities and different pathology. And expand-
ing the sample size may yield a better result. Thirdly, some
unpublished data (such as negative report, not written in
English and lack of studies in African population) may po-
tentially influence the results of our meta-analysis. At last,
different genotyping strategies may contribute to the bias
in the analysis.
Recently several meta-analyses systematically reviewed
the potential association of rs3746444 polymorphism with
susceptibility to diseases [40-45,74-77]. However, the re-
sults were controversial across these meta-analyses. Such
discrepancies in the results of these systematic reviews
may due to different search periods, databases searched,
inclusion and exclusion criteria. Our efforts to search the
maximum range of databases yielded the most compre-
hensive studies in the similar time period especially the
most recent publications [53,59]. Further, diagnosis of
cancer is largely relied on confirmation by histology,imaging or pathology. Some of the other studies omitted
this fundamental condition. Most importantly, deviations
from Hardy-Weinberg equilibrium can inflate the chance
of a false-positive association, and sensitivity analysis
should be performed, pooling with and without studies
not in HWE, to test the robustness of the results [78,79].
Only few of other studies performed sensitivity analysis,
which may limit the reliability of their conclusions. Al-
though some studies claimed that their studies were in
HWE, a careful examination of the studies revealed that
the data did not reach HWE. In conclusion, in our study,
relevant literatures selected from broad databases with
stringent standards would be expected to provide a more
reliable conclusion.Conclusions
In summary, though with limitations, our meta-analysis
suggested that hsa-mir-499 rs3746444 T >C polymorphism
is associated with the risk of cancer, especially in Asians,
mainly in Chinese and Iranians. However, rs3746444 T >C
polymorphism is negatively associated with the risk of
esophageal cancer. Larger studies from different ethnic
groups and studying different types of cancers with detailed
information are needed to further clarify the association be-
tween rs3746444 polymorphism and cancer risk.Additional files
Additional file 1: The PRISMA 2009 Checklist.
Additional file 2: Forest plot of ORs for the association of hsa-miR-499
rs3746444 T>C polymorphism with cancer risk in different situations.
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versus TT (dominant) and (E) CC versus TC/TT (recessive). Figure S3. Forest
plot of ORs for the association of hsa-miR-499 rs3746444 T>C polymorphism
with cancer risk is illustrated by country in Asia. (A) C versus T; (B) TC versus
TT; (C) CC versus TT; (D) TC/CC versus TT (dominant) and (E) CC versus TC/TT
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